Article

Expanded indications offer successful outcomes for many more patients

With the FDA's recent approval of expanded indications for Alcon's LADARVision system, I can now treat up to 93% of my myopic LASIK candidates with a customized wavefront-guided procedure.

The current indications are for the correction of myopia up to -8 D, with or without astigmatism up to -4 D, the broadest treatment range for any wavefront-guided system that I am familiar with.

Using this method, the laser treats exactly at the same area where the measurements were obtained, regardless of unavoidable cyclotorsion, allowing the most precise treatment. I also think the fact that we no longer need to be concerned about angle kappa considerations is very important.

Preoperatively, the mean spherical equivalent was -4.10 D (-0.88 to -10.63 D). Mean sphere was -3.57 D, and went as high as -9.75 D. Mean cylinder was -1.07 D, but ranged as high as -5 D.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.